Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
3
75%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 41 (25.0%)
N/A3 (75.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_4

Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17

NCT03558971
completednot_applicable

Depression, Adversity, and Stress Hormones (DASH) Study

NCT03195933
terminatednot_applicable

Low-dose Cortisol in Chronic Posttraumatic Stress Disorder

NCT00362661
completednot_applicable

Cortisol in the Treatment of Phobias

NCT00451750

Clinical Trials (4)

Showing 4 of 4 trials
NCT03558971Phase 4

Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17

Completed
NCT03195933Not Applicable

Depression, Adversity, and Stress Hormones (DASH) Study

Completed
NCT00362661Not Applicable

Low-dose Cortisol in Chronic Posttraumatic Stress Disorder

Terminated
NCT00451750Not Applicable

Cortisol in the Treatment of Phobias

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4